About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6731 record(s)
Req # A-2019-001739
Adverse Drug Reactions (ADRs) for PANTOPRAZOLE. Report numbers: E2B_02774301, E2B_02774325, E2B_02774310, E2B_02774380, E2B_02774613, E2B_02774627, E2B_02780623, E2B_02781431, E2B_02781452, E2B_02781691, E2B_02781703, E2B_02783238, E2B_02783269,…Organization: Health Canada
February 2025
Req # A-2020-000641
Adverse Drug Reactions (ADRs) for Tylenol. Report numbers: 000176937, 000176984, 000177086, 000177175, 000177185, 000177196, 000177202, 000177222, 000177242, 000177692, 000177723, 000177956, 000178002, 000178011, 000178187, 000178299, 000178336,…Organization: Health Canada
February 2025
Req # A-2020-000906
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108703-429.Organization: Health Canada
February 2025
Req # A-2020-001123
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03099121, E2B_03106275, 000735796, 000737567, E2B_03000150, E2B_02981243, E2B_03114742, E2B_03140965, E2B_03145024, E2B_03147019, E2B_03160597, E2B_03000163,…Organization: Health Canada
February 2025
Req # A-2020-001473
Adverse Drug Reactions (ADRs) for Leflunomide. Report numbers: E2B_03078618 E2B_03162049 E2B_03023436 E2B_03024777 E2B_03025146 E2B_03025685 E2B_03026420 E2B_03026566 E2B_03121896 E2B_03079067 E2B_03028636 E2B_03079213 E2B_03016886.Organization: Health Canada
February 2025
Req # A-2020-001512
Adverse Drug Reactions (ADRs). Report numbers: E2B_03020957, E2B_03022194, E2B_03022481, E2B_03023411, E2B_03023680, E2B_03024602, E2B_03025480, E2B_03027899, E2B_03027935, E2B_03027941, E2B_03027953, E2B_03027961, E2B_03028067, E2B_03028400,…Organization: Health Canada
February 2025
Req # A-2020-001882
Adverse Drug Reactions (ADRs). Report numbers: E2B_03404024, E2B_03406168, E2B_03417674, E2B_03421022, E2B_03423210, E2B_03433756, E2B_03430876, E2B_03432544, E2B_03435242, E2B_03457500, E2B_03440751, E2B_03451475, E2B_03470263, E2B_03473583,…Organization: Health Canada
February 2025
Req # A-2021-000115
Adverse Drug Reactions (ADRs) for Celexa. Report numbers: 916050, 914287, E2B_03195941, E2B_03266230, 920937, E2B_03306917, 919838, 920655. ADRs for Clopixol. Report numbers: 917413, 920812. ADRs for Fluanxol. Report numbers: 913790, 913799,…Organization: Health Canada
February 2025
Req # A-2021-000378
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-102437-273.Organization: Health Canada
February 2025
Req # A-2021-000926
Adverse Drug Reaction (ADR) for NITROGLYCERIN. Report number: E2B_03716623.Organization: Health Canada
February 2025